Navigation Links
New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
Date:11/30/2009

SEATTLE, Nov. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines. The results were presented in a paper titled "Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile," by Laura Gatti et al. that was published in the online edition of the journal Molecular Pharmaceutics. Platinum-based compounds, such as cisplatin and oxaliplatin, are the cornerstone in the treatment of testicular, ovarian, colorectal, lung and other cancers but their effectiveness is limited by the relatively low therapeutic ratio, the ratio of the maximally tolerated dose of the drug to the effective dose, and the frequent occurrence of drug resistance leading to cancer recurrence. The novel bis-platinum compounds represent a completely new class of platinum-based drugs called bisplatinates.

The bis-platinum based compounds, unlike the currently approved platinum-based compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The research demonstrated through cancer cell assays and animal tumor models that the bis-platinum complexes exhibited greater cytotoxic potency and anti-tumor effect compared to cisplatin and oxaliplatin. There was more than a 200-fold increase in percent accumulation in tumor cells of the bisplatinum compounds compared to cisplatin and oxaliplatin. The bisplatinates were substantially more active against human tumors grown in an immunodeficient preclinical model than the standard palatinate compounds, oxaliplatin, carboplatin and cisplatin. Furthermore, the bis-platinum compounds demonstra
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pragmedic Implements World-Class Healthcare Solution for Emaar Healthcare
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan
4. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
6. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
7. CellGard ES NU-480 Class II Biological Safety Cabinet Now Available
8. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
9. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
10. ACTE Releases Paper Highlighting Policy Trend to Support Recognition of Academic Credit for CTE Classes
11. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... YORK, Oct. 23 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... notice from The,Nasdaq Stock Market ("Nasdaq") stating that ... a minimum bid price of,$1.00 per share, has ... the Company that it now has until January ...
... Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... abstract entitled "Phase I Trial,of Oncolytic Reovirus ... Advanced Solid Cancers" will be,available in the ... official journal of the International Society for ...
... Md., Oct. 23 MedImmune today announced,that researchers ... at the Annual Meeting of the American College ... the Moscone Center in San Francisco, California., ... solutions for patients,struggling with systemic autoimmune rheumatic diseases," ...
Cached Biology Technology:Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3
(Date:5/22/2013)... Trial (NLST) investigators also conclude that the 20 ... computed tomography (LDCT) versus chest X-ray (CXR) screening ... achievable at experienced screening centers in the United ... share with their patients about the benefits and ... publication in the New England Journal of ...
(Date:5/22/2013)... that can detect molecular variants in chemical mixtures ... most important, though time-consuming, processes in analytical chemistry. ... , post-doctoral researcher David Patterson, Professor of Physics John ... Free-Electron Laser Science (CFEL) in Hamburg, Germany developed a ... molecular variants apart, and to determine how much variant ...
(Date:5/22/2013)... 2013)The omega 3 fatty acids in fish oil have ... so that the American Heart Association currently recommends eating ... fatty varieties rich in omega 3s. However, the mechanism ... a new study, scientists led by Jason R. Carter ... by providing evidence that fish oil might specifically counteract ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... Foundation has granted two Clemson University professors $250,000 to ... 10 times smaller in diameter than a human hair ... both money and time compared to more traditional methods ... work like a sponge to draw up fluids from ...
... ESA and European industries have updated the planning of ... of 27 October 2008 for the GOCE satellite. ... GOCE from the Plesetsk Cosmodrome in northern Russia were ... one of the units of the guidance and navigation ...
... dinosaurs that perished in a catastrophic event 72.5 million ... frill on the back of the skull ornamented with ... their nose and eyes which lends them their name: ... keratin. According to Dr. Philip Currie, renowned palaeontologist ...
Cached Biology News:A new dinosaur species, Pachyrhinosaur lakustai, unveiled from Pipestone Creek, Alberta, Canada 2
CMRL Medium-1066 (1X) liquid...
... The PhosphatidylEthanolamine-Binding Protein (PEBP) does not ... protease inhibitors. PEBP is expressed ... testis, ovary, muscle, and stomach. ... in is exerting inhibitory activity against ...
karyopherin alpha2 (2G7)...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Biology Products: